Net benefit separation and the determination curve: A probabilistic framework for cost-effectiveness estimation

Considerations regarding clinical effectiveness and cost are essential in comparing the overall value of two treatments. There has been growing interest in methodology to integrate cost and effectiveness measures in order to inform policy and promote adequate resource allocation. The net monetary benefit aggregates information on differences in mean cost and clinical outcomes; the cost-effectiveness acceptability curve was then developed to characterize the extent to which the strength of evidence regarding net monetary benefit changes with fluctuations in the willingness-to-pay threshold. Methods to derive insights from characteristics of the cost/clinical outcomes besides mean differences remain undeveloped but may also be informative. We propose a novel probabilistic measure of cost-effectiveness based on the stochastic ordering of the individual net benefit distribution under each treatment. Our approach is able to accommodate features frequently encountered in observational data including confounding and censoring, and complements the net monetary benefit in the insights it provides. We conduct a range of simulations to evaluate finite-sample performance and illustrate our proposed approach using simulated data based on a study of endometrial cancer patients.

[1]  Chien-Chih Chen,et al.  Real-world cost-effectiveness of laparoscopy versus open colectomy for colon cancer: a nationwide population-based study , 2017, Surgical Endoscopy.

[2]  D. Lin,et al.  Linear regression analysis of censored medical costs. , 2000, Biostatistics.

[3]  Andrew Briggs,et al.  Statistical Analysis of Cost-Effectiveness Data , 2006 .

[4]  A J Moskowitz,et al.  Bayesian estimation of cost-effectiveness ratios from clinical trials. , 1999, Health economics.

[5]  J. Carroll,et al.  Cost-Effectiveness of Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Stroke Prevention , 2018, Stroke.

[6]  D. Fan,et al.  Cost-effectiveness analysis of fecal microbiota transplantation for inflammatory bowel disease , 2017, Oncotarget.

[7]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[8]  I. Nazareth,et al.  Modelling the cost-effectiveness of preventing major depression in general practice patients , 2013, Psychological Medicine.

[9]  D Polsky,et al.  Confidence intervals for cost-effectiveness ratios: a comparison of four methods. , 1997, Health economics.

[10]  N. Zethraeus,et al.  Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.

[11]  Arman Oganisian,et al.  A causal approach to analysis of censored medical costs in the presence of time-varying treatment , 2017 .

[12]  Elisabeth Fenwick,et al.  Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation , 2006, BMC Health Services Research.

[13]  J. Jansen,et al.  An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference? , 2018, Health policy.

[14]  Nandita Mitra,et al.  Propensity score and doubly robust methods for estimating the effect of treatment on censored cost , 2016, Statistics in medicine.

[15]  A H Briggs,et al.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.

[16]  M. Kaess,et al.  A cost-effectiveness analysis of school-based suicide prevention programmes , 2018, European Child & Adolescent Psychiatry.

[17]  Shihti Yu,et al.  On the choice between sample selection and two-part models , 1996 .

[18]  D. Mant Prevention , 1994, The Lancet.

[19]  M. Randall,et al.  Adjuvant radiotherapy in endometrial carcinoma. , 2005, The oncologist.

[20]  Andrew H Briggs,et al.  Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[21]  A J Moskowitz,et al.  Problems with Interval Estimates of the Incremental Cost—Effectiveness Ratio , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  Nandita Mitra,et al.  Analyzing medical costs with time‐dependent treatment: The nested g‐formula , 2018, Health economics.

[23]  Daniel F Heitjan,et al.  Bayesian estimation of cost‐effectiveness from censored data , 2004, Statistics in medicine.

[24]  Anthony C. Davison,et al.  Bootstrap Methods and Their Application , 1998 .

[25]  Margaret S Pepe,et al.  Using the ROC curve for gauging treatment effect in clinical trials , 2006, Statistics in medicine.

[26]  Nandita Mitra,et al.  A doubly robust approach for cost–effectiveness estimation from observational data , 2018, Statistical methods in medical research.

[27]  Andrew Briggs,et al.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.

[28]  Donald B. Rubin,et al.  Bayesian Inference for Causal Effects: The Role of Randomization , 1978 .

[29]  B. Delaney,et al.  Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care , 2000, The Lancet.

[30]  A R Willan,et al.  Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. , 1996, Health economics.

[31]  Andrew Briggs,et al.  Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[32]  A. Briggs,et al.  Statistical Analysis of Cost-effectiveness Data: Willan/Statistical Analysis of Cost-effectiveness Data , 2006 .

[33]  Jeffrey D Blume,et al.  Measuring and illustrating statistical evidence in a cost-effectiveness analysis. , 2008, Journal of health economics.

[34]  D. Heitjan,et al.  EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT. , 2013, The annals of applied statistics.

[35]  Michael M. Braun,et al.  Diagnosis and Management of Endometrial Cancer. , 2016, American family physician.

[36]  D.,et al.  Regression Models and Life-Tables , 2022 .

[37]  P. Scuffham,et al.  Cost-effectiveness of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort - The WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care). , 2015, International journal of cardiology.

[38]  Nobuyuki Susumu,et al.  Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[39]  J. Cavanaugh,et al.  Partial Likelihood , 2018, Wiley StatsRef: Statistics Reference Online.